AGI's Pulmostrat™ test is targeted for patients with early stage lung cancer. The test will subclassify patients into those with a low-, moderate-, or high-risk of cancer recurrence following surgical resection of their primary tumor. Pulmostrat is only for those patients without distant metastases (i.e. Stage 1 or Stage 2 non-small cell lung cancer patients) with surgically operable disease. Recent studies have demonstrated that some, but likely not all, early stage lung cancer patients could benefit from the use of adjuvant cytotoxic chemotherapy. Since Pulmostrat classifies patients based upon their relative risk of cancer recurrence, it will help patients and oncologists make more informed decisions when considering treatment options.

Pulmostrat is an antibody-based immunohistochemistry test that uses standard IHC technology that is widely available. The laboratory that makes the original tumor diagnosis can suggest Pulmostrat to the ordering pathologist or oncologist. Because it uses standard pathology laboratory protocols and equipment, the test should be relatively inexpensive and the current reimbursement system should allow for Pulmostrat to be paid for by third party insurers without special reimbursement approval or provisions.

Note that Pulmostrat testing requires a histological diagnosis of adenocarcinoma or non-adenocarcinoma to determine which four antibodies in the Pulmostrat test to use. In the case of small core or needle biopsies, this classification can be very difficult and we recommend the use of AGI's Pulmotype product to help with this classification. See Pulmotype for more information on this test.